$VTYX double this morning. Count me as maximally skeptical. This is nothing more than classic, bubble-market thesis creep. Obesity fail, who cares, let's just pivot the plot to CV risk reduction! The $200-300M market cap biotech bucket has been a sweet spot for investors, but also, some really eye-rolling claims.
